Extended Data Fig. 7: CHPG treatment affects myelin Ca²⁺ transients.

A: Representative time-lapse images with AQuA2-detected transient shown (top) and Fire LUT (bottom) of mbp:mem:GCaMP7s expressing oligodendrocytes treated with DMSO and CHPG after immediate application of compounds (top rows), 1 h (middle rows) and 16 h (bottom rows) after drug application (hpt). Scale bar, 10 µm. B: Avg. dF/F of myelin Ca²⁺ transients immediately after CHPG application (0 hpt) (DMSO N = 16, mean: 0.87, SD: ±0.17; CHPG N = 19 mean: 0.87, SD: ±0.12) (unpaired t-test: p-value = 0.6774). C: Avg. dF/F of myelin Ca²⁺ transients 1 h after CHPG application (1 hpt) (DMSO N = 16, mean: 0.82, SD: ±0.23; CHPG N = 19, mean: 1.08, SD: ±0.55) (Mann–Whitney test: p-value = 0.0275). D: Avg. dF/F of myelin Ca²⁺ transients 16 h after CHPG application (16 hpt) (DMSO N = 15 mean: 0.66, SD: ±0.15; CHPG N = 10 mean: 0.64, SD: ±0.17) (unpaired t-test: p-value = 0.7351). E: Mean of the average dF/F of myelin Ca²⁺ transients after 0, 1 and 16 hpt after CHPG/DMSO application. F: Frequency of myelin Ca²⁺ transients per animal immediate after CHPG application (0 hpt) (DMSO N = 23, mean: 63.2 SD: ±86.53; CHPG N = 19, mean: 136, SD: ±85.49) (Mann–Whitney test: p-value = 0.0005). G: Frequency of myelin Ca²⁺ transients per animal 1 h after CHPG application (1 hpt) (DMSO = 16, mean: 50.15, SD: ±61.26; CHPG N = 19, mean: 133.1, SD: ±133.0) (Mann–Whitney test: p-value = 0.0159). H: Frequency of myelin Ca²⁺ transients per animal 16 h after CHPG application (16 hpt) (DMSO N = 16, mean: 103.1, SD: ±81.94; CHPG N = 13 mean: 98.40, SD: ±118.1) (Mann–Whitney test: p-value = 0.3980). I: Mean Frequency of myelin Ca²⁺ transients over treatment, 1 hpt and 16 hpt.

Source data